Treatment and Management of Dementia Due to Alzheimer’s Disease
- 824 Downloads
Alzheimer’s disease (AD) is a progressive neurological disorder typically associated with episodic memory loss as the initial symptom, but individuals <65 years old may present with executive dysfunction, word finding difficulties, or visual processing deficits. In those with AD, curative treatments are not available, but there are interventions which may modify disease course, symptom appearance and severity, enhance quality of life for patient and caregivers, and maintain safety. Both pharmacological and non-pharmacological interventions are important.
KeywordsAlzheimer’s disease Treatment Management Dementia
Compliance with Ethics Guidelines
Conflict of Interest
Jennifer Rose V. Molano, Robin Bratt, and Rhonna Shatz declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.•Ngandu T et al. A 2 year multi-domain intervention of diet, exercise, cognitive training and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER); a randomized controlled trial. Lancet. 2015. doi: 10.1016/S0140-6736(15)60461-5. Large, randomized controlled trial showing the importance of lifestyle modification in modifying cognitive decline.PubMedGoogle Scholar
- 24.Kavanaugh S, VanBaelen B, Schӓuble B. Long term effects of galantamine on cognitive function in Alzheimer’s disease: a large scale international retrospective study. J Alzheimer’s Disord. 2011;27:521–30.Google Scholar
- 28.•Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatri. 2011;23(3):372–8. Good review of studies that have investigated the switch of cholinesterase inhibitors in AD, with a practical approach in addressing intolerance and lack of efficacy with these medications.CrossRefGoogle Scholar
- 32.Rosalynn Carter Institute for Caregiving. What Makes A Caregiver Program Effective? 2012. http://www.rosalynncarter.org/what_makes_caregiver_programs_effective/.
- 34.••Kales HC and Gitlin LN. Assessment and management of behavioral and psychological symptoms of dementia. BMJ 2015;5:350:h369 doi: 10.1136/bmjJ369. Excellent summary of NPS, factors contributing to symptoms, evidence for non-pharmacological and pharmacological interventions, theoretical framework and strategies for assessment, evaluations and management strategies for the clinician, initiating treatment plan and suggestions for collaboration and referral. Comprehensive reference list includes many historically and currently relevant articles on which knowledge is being built.
- 45.Ortega V et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014;1, CD009125.Google Scholar
- 47.Federal Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
- 50.Seitz DP et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2, CD008819.Google Scholar
- 66.Ma H et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimer ’s Dis. 2014;42(3):915–37.Google Scholar
- 68.Declerq T. Withdrawal versus continuation of chronic antipsychotics drugs for behavioral and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2002; 3. CD007726.Google Scholar